On July 1st Concit Pharma received approval of protocol for the Phase IIa study in L-DOPA induced dyskinesia. The approval is an important milestone and strongly supports Concit Pharma’s development plans.
Concit Pharma will present JM-010 at the Movement Disorder Society meeting in Sydney, Australia June 16-20. The preclinical data suppporting the efficacy and safety of JM-010 as a new drug for treatment of L-DOPA induced dyskinesia will be presented on a poster. A copy of the poster can be obtained upon request (email@example.com).
On October 1st Concit Pharma and Neurobiological Research Unit, Copenhagen National Hospital (Rigshospitalet) has initiated a research project supported by The Danish National Advanced Technology Foundation. The project will during the next two years focus on identification and characterization of new drugs for treatment of L-DOPA induced dysinesia.
Concit Pharma raises new capital and wellcomes Dr. Magnus Persson and Dr. Carsten Schou as new members of the board of directors. Concit Pharma has projects focusing L-DOPA induced dyskinesia and neuropathic pain and the new investment from Novo AS and Seed Capital will make it possible to further progress the projects towards testing in […]
Concit Pharma raises new capital in a seed round extension. Novo Seeds, the seed fund of Novo A/S, joins as new investor Concit Pharma, which was founded in 2010, develops novel medicine by reformulation and repositioning of safe and efficacious drugs to facilitate development and reduce risks. Concit Pharma is initially focused on projects within […]